In T2D mice, oral administration of Proxyfan can lower blood glucose and glycosylated hemoglobin A1c (HbA1c), and intracerebroventricular administration of Proxyfan can increase plasma insulin levels via a glucose-independent mechanism (116). The gene discussed is INS; the disease is type 2 diabetes mellitus.